Countries View catalog
Blog · For physicians

Peptides: what physicians need to know

The questions people ask most about peptides, GLP-1s and how they are regulated, with the evidence for and against: PubMed-verified studies, regulators' decisions, news and the arguments of peptide supporters. Every fact is linked.

Articles

Regulation

Counterfeit Ozempic, compounded tirzepatide: indictment and recall

In September 2026 the U.S. Department of Justice charged two Indian nationals with smuggling counterfeit Ozempic from China, and FDA classified a North Carolina pharmacy's recall of compounded tirzepatide vials for lack of sterility assurance. Two fronts in the same GLP-1 supply chain.

October 27, 2026 · 6 min read · 15 sources Read article →
Regulation

Peptide compounding policy: who is lobbying the White House

FDA's interim access policy for compounded peptides is under White House review, and six outside parties asked to be heard before it comes out. Who they are, what the document can and cannot do, and how thin the human evidence behind it still is.

October 25, 2026 · 6 min read · 23 sources Read article → Clinical practice

What is a peptide? Explained in five minutes

If amino acids are letters, peptides are short words and proteins are books. This first step explains the basic idea, with insulin as the example.

October 20, 2026 · 3 min read · 14 sources Read article →
Regulation

Exosomes that aren't exosomes: what FDA found in 2025–2026

An August 2026 warning letter says a manufacturer's "exosome" process for hair, facial and sexual rejuvenation does not appear to isolate exosomes, and that its sterility tests were run on frozen samples. So what is in the vial going onto microneedled skin?

October 12, 2026 · 7 min read · 18 sources Read article → Market

Retatrutide: Lilly takes an aesthetic clinic to court

In August 2026, Eli Lilly sued a California med spa, a compounding pharmacy and four "research use only" sellers over a drug that is still in Phase 3. It says it has reported more than 200 individuals and entities to the FDA, the Justice Department and licensing boards. What changed for clinics that administer it.

October 12, 2026 · 6 min read · 21 sources Read article →
Evidence

GHK-Cu (copper peptide): the mechanism of action, step by step

From copper to matrix, from matrix to cell and from cell to gene: what has actually been measured about how GHK-Cu works in skin, with every human study we could verify.

October 9, 2026 · 7 min read · 37 sources Read article → Clinical practice

The "GLP-1 face": what the studies show and what the aesthetic physician can offer

Semaglutide and tirzepatide have brought a new population into the aesthetic practice: patients who lost weight and see a hollower face. What imaging measures, what patients ask for, and the level of evidence behind the treatments.

October 9, 2026 · 6 min read · 15 sources Read article → Evidence

Peptides and skin healing: what the studies show for laser, microneedling and surgery

Thymosin β4, BPC-157 and GHK-Cu have decades of data in wounds, burns and scars, nearly all of it in animals. What the studies say, which molecule each one used, and what happened when thymosin β4 reached human trials.

October 9, 2026 · 6 min read · 21 sources Read article →
Trends

Exosomes versus peptides: what is actually being applied to the skin

Exosomes are the most visible trend in regenerative aesthetics. We explain what they are, why it is so hard to know what a vial contains and what the trials show, and we compare them with a drug class defined by its sequence.

October 9, 2026 · 6 min read · 21 sources Read article → Evidence

Peptides and hair loss: copper, thymosin β4 and biomimetics against the evidence

The hair clinic now sees copper peptides, biomimetic lotions and patients shedding hair on GLP-1 drugs. Which molecule was studied, in what model and with what result, next to minoxidil and finasteride.

October 9, 2026 · 7 min read · 22 sources Read article → Evidence

Matrixyl and signal peptides: what the skin trials show

A five-amino-acid fragment of type I procollagen became the most studied cosmetic peptide. Origin, mechanism, every vehicle-controlled trial that can be verified in PubMed, the comparison with tretinoin and how the penetration problem is being solved.

October 9, 2026 · 7 min read · 19 sources Read article → Evidence

PRP in aesthetics: the biologic nobody questions

A peptide is asked for its sequence, its purity and a certificate of analysis. Platelet-rich plasma, which has none of the three, is asked for a centrifuge. What the evidence for PRP shows in hair, face, scars and melasma, and why aesthetic practice measures it with a different yardstick.

October 9, 2026 · 6 min read · 17 sources Read article →
Evidence

DSIP: the delta sleep peptide, fifty years on

DSIP was isolated in 1977 as a possible "sleep factor". Its sequence, its passage into the brain and its half-life of minutes are known today, but not its gene or its receptor. We review what human studies showed in sleep, withdrawal and the stress axis, and where the evidence ends.

October 9, 2026 · 6 min read · 18 sources Read article → Market

How a peptide is made: solid-phase synthesis explained for physicians

Behind every vial is more than sixty years of chemistry, honored with a Nobel Prize and now run at the scale of tons. Knowing how a peptide is built, what impurities it can carry and how it is controlled makes any analysis easier to read.

October 9, 2026 · 7 min read · 18 sources Read article → Evidence

Peptides in oncology: the approved drugs already treating cancer

Long before semaglutide, peptides had earned a place in prostate cancer, neuroendocrine tumors and myeloma, with phase 3 trials published in the leading journals. This is a drug-by-drug review of that evidence.

October 9, 2026 · 5 min read · 21 sources Read article → Market

Orforglipron: the first GLP-1 pill that is not a peptide

The FDA approved orforglipron for weight management on 1 April 2026. It is a small molecule taken without food or water restrictions that may expand the market; for weight loss, peptides still set the benchmark.

October 9, 2026 · 6 min read · 14 sources Read article → Trends

The other side: why doctors and patients defend peptides

The regulators' criticisms are real. So is the fact that more than 80 peptide drugs help millions of people today, that demand keeps growing and that many doctors see results in their practice. These are the arguments of peptide supporters, in their own words.

October 9, 2026 · 4 min read · 15 sources Read article →
Trends

A century of peptide therapeutics: from insulin to semaglutide

The first insulin injection was given in January 1922. A century later, more than 80 peptide drugs are on the market and GLP-1 analogues rank among the best-selling medicines in the world. This is the story of a mature drug class, and of how chemistry solved its limitations.

October 9, 2026 · 5 min read · 14 sources Read article → Evidence

GLP-1s beyond weight: the hard-outcome trials

Heart attack, kidney, sleep apnea, fatty liver, heart failure and the knee: six areas where semaglutide or tirzepatide already has randomized phase 3 trials. This is the evidence that makes the class more than a weight-loss treatment.

October 9, 2026 · 4 min read · 12 sources Read article → Evidence

Tirzepatide and the GIP paradox: why adding an "obesogenic" hormone worked

In 2002, mice lacking the GIP receptor resisted obesity. Two decades later, an agonist of that same receptor, combined with GLP-1, beat semaglutide in head-to-head trials. What explains the paradox, and where the evidence ends.

October 9, 2026 · 5 min read · 15 sources Read article → Evidence

After semaglutide: CagriSema, orforglipron, MariTide and the estimand trap

The next generation of obesity drugs arrives with double-digit numbers. But the same molecule can "lose" 20.4% or 22.7% depending on the estimand. How to read the results before they reach the clinic.

October 9, 2026 · 3 min read · 17 sources Read article → Evidence

Cagrilintide and amylin: the other satiety hormone

Amylin leaves the β-cell together with insulin and curbs food intake through a pathway distinct from GLP-1. From 2005's pramlintide to once-weekly cagrilintide, this is what the trials show and where they stop.

October 9, 2026 · 5 min read · 16 sources Read article →
Evidence

GLP-1s: muscle, rebound, eyes and pancreas. What the data say

Four questions dominate conversations about semaglutide and tirzepatide: do you lose muscle? does the weight come back when you stop? do they harm vision? and the pancreas? Answers from trials and regulators.

October 9, 2026 · 3 min read · 14 sources Read article → Evidence

BPC-157 in the laboratory: tendon, gut and blood vessels

Three decades of animal models describe BPC-157 as a repair peptide with an unusual pattern: the same effect in tendon, gut mucosa and endothelium. What those studies show, tissue by tissue, which mechanisms independent laboratories confirmed, and where the evidence ends.

October 9, 2026 · 5 min read · 15 sources Read article → Clinical practice

Semaglutide and alcohol: three trials and a warning removed

Patients reported it in the clinic: on GLP-1s they drank less. Between 2025 and 2026 three randomized trials arrived, one in The Lancet. And in January 2026 the FDA asked for the suicidal-ideation warning to be removed.

October 9, 2026 · 2 min read · 15 sources Read article → Evidence

SS-31 (elamipretide): the mitochondrial peptide that reached the FDA

A tetrapeptide that binds cardiolipin in the inner mitochondrial membrane won FDA accelerated approval for Barth syndrome in 2025. What its trials showed, where they failed and what still needs confirming.

October 9, 2026 · 5 min read · 15 sources Read article → Evidence

NAD+ in humans: precursors, infusions and what the trials measure

NAD+ declines with age in human tissues and its oral precursors raise it consistently. The clinical question is a different one: what changes in study subjects' outcomes, and what is known about NAD+ given directly by intravenous infusion.

October 9, 2026 · 5 min read · 14 sources Read article →
Evidence

BPC-157: from Rogan's podcast to an FDA vote

Robert F. Kennedy Jr. said he used it. An FDA committee voted 8 to 6 in its favor. And PubMed still has not one controlled trial in humans. What changed in 2026 and what did not.

October 9, 2026 · 3 min read · 21 sources Read article → Trends

GLOW, KLOW and Wolverine: the logic of regenerative blends

Blends of BPC-157, TB-500, GHK-Cu and KPV bring four tissue-repair mechanisms into a single vial. The synergy hypothesis is appealing; the data that test it are only beginning.

October 9, 2026 · 6 min read · 16 sources Read article → Evidence

Kisspeptin: real science, wrong molecule?

Human kisspeptin studies are among the best in this field: IVF, sexual desire, functional MRI. But almost all use single doses of kisspeptin-54 (subcutaneous injection or intravenous infusion) in a clinical or research setting. What circulates on the market is something else.

October 9, 2026 · 2 min read · 15 sources Read article → Evidence

GLP-1s and the brain: Parkinson's, Alzheimer's and mood, between signal and trial

Cohorts link GLP-1 agonists to less dementia, and a Parkinson's trial came out positive in NEJM. But the large semaglutide Alzheimer's trial and the phase 3 exenatide Parkinson's trial were negative. What is known today, trial by trial.

October 9, 2026 · 5 min read · 14 sources Read article → Trends

GHRP-6, GHRP-2 and ghrelin: when pharmacology discovered a hormone

In 1984 a synthetic hexapeptide released growth hormone while no one knew which receptor it acted on. Fifteen years later that question led to ghrelin and, later still, to drugs approved in Japan and the United States.

October 9, 2026 · 5 min read · 14 sources Read article → Evidence

CJC-1295, ipamorelin and MK-677: the GH and IGF-1 debate

Raising growth hormone sounds like youth. Human studies show these compounds do raise it, and also what it costs and what is still unknown.

October 9, 2026 · 4 min read · 15 sources Read article →
Evidence

Tesamorelin: the GHRH analog that did clear the FDA

Among the peptides that stimulate growth hormone, tesamorelin is the one with phase 3 trials and FDA approval since 2010. Its data show what this mechanism achieves in humans and what it requires monitoring for.

October 9, 2026 · 5 min read · 15 sources Read article → Evidence

MOTS-c and the mitochondrial peptides: what is known and where the evidence ends

MOTS-c is a 16-amino-acid peptide hidden in mitochondrial DNA. It has solid biology in mice, genetic associations in humans and only one analog tested in a small clinical trial.

October 9, 2026 · 5 min read · 14 sources Read article → Trends

Epitalon, MOTS-c, NAD+ and SS-31: longevity between promise and proof

"Anti-aging" peptides are the fastest-growing part of the conversation. What do they have in common? A lot of interesting biology and no human evidence that they slow aging.

October 9, 2026 · 2 min read · 12 sources Read article → Evidence

AOD-9604: the GH fragment meant to burn fat without touching glucose

A 16-amino-acid peptide derived from the C-terminus of growth hormone, with solid laboratory data, six human safety trials and a phase 2b trial that did not confirm weight loss.

October 9, 2026 · 5 min read · 13 sources Read article → Evidence

TB-500 is not thymosin beta-4: fragment vs protein

Almost everything said about TB-500 comes from studies of full-length thymosin beta-4, a 43-amino-acid protein. TB-500 is a 7-amino-acid fragment. The FDA found no case in the medical literature of it being given to patients.

October 9, 2026 · 3 min read · 17 sources Read article → Evidence

Oral collagen: the peptide your patients already take

Hydrolyzed collagen is probably the most widely consumed "peptide". Meta-analyses show benefits for skin and joints, but the skin effect fades when only independent or high-quality trials are analyzed.

October 9, 2026 · 4 min read · 12 sources Read article →
Evidence

Ipamorelin: the "selective" GH secretagogue, from Novo Nordisk's lab to postoperative ileus

Ipamorelin was the first secretagogue to release GH in animals without raising ACTH or cortisol. Its clinical program bet on postoperative ileus, not aging, and fell short there.

October 9, 2026 · 6 min read · 16 sources Read article → Evidence

GHK-Cu: four decades of papers, few trials

The copper peptide is a cosmetics star and now a syringe star too. Topical trials give mixed results, the injectable route has no human trials, and about a third of the literature carries the same group's byline.

October 9, 2026 · 2 min read · 15 sources Read article → Evidence

Sermorelin: the GHRH fragment that was an approved drug

Sermorelin, GHRH(1-29)NH2, held two FDA approvals in pediatrics and left the market without the agency finding safety or effectiveness reasons. This is what its trials in children and older adults showed, and where the evidence ends.

October 9, 2026 · 6 min read · 13 sources Read article → Evidence

PT-141 in men: a central, not vascular, mechanism

Before it was approved for women, bremelanotide was studied in men with erectile dysfunction, including men who did not respond to sildenafil. What those trials showed, how it acts on the MC4R receptor and where the evidence ends.

October 9, 2026 · 5 min read · 14 sources Read article → Evidence

Semax, Selank and DSIP: what is behind the nootropic peptides

Semax is registered in Russia as nasal drops and promoted worldwide as a cognitive enhancer. Selank as an anxiolytic. DSIP for sleep. We review the trials and what the FDA found in 2026.

October 9, 2026 · 2 min read · 15 sources Read article → Evidence

LL-37 and antimicrobial peptides: the body's answer to resistance

Humans make a single peptide of the cathelicidin family, LL-37, and its synthesis depends in part on vitamin D. Antimicrobial peptides are already in the pharmacy, but several new candidates have fallen by the wayside.

October 9, 2026 · 5 min read · 16 sources Read article →
Evidence

CJC-1295 and DAC: the GHRH analog that anchors to albumin

A GHRH fragment acts for minutes. By binding it covalently to albumin, CJC-1295 stretched its effect to days in healthy adults without erasing the natural GH pulse. What the studies showed, how it differs from the "no-DAC" version, and why its development stopped.

October 9, 2026 · 5 min read · 12 sources Read article → Evidence

Melanotan II and PT-141: chemical cousins, opposite stories

Both act on melanocortin receptors. One went through phase 3 trials and is approved. The other is sold for tanning and has a growing list of reports of new moles and melanomas. Why the difference.

October 9, 2026 · 2 min read · 17 sources Read article → Evidence

IGF-1 LR3 and mecasermin: the lab analog and the approved drug

IGF-1 has had an approved drug since 2005, mecasermin, with a narrow pediatric indication and a demanding label. IGF-1 LR3 is a different molecule: an analog engineered to escape the binding proteins, highly potent in the lab and with animal data only.

October 9, 2026 · 5 min read · 13 sources Read article → Clinical practice

How to read a peptide certificate of analysis

A well-made certificate of analysis is the researcher's best tool for knowing what is in the vial. This guide explains what each test measures (HPLC, mass spectrometry, content, water, endotoxins, solvents) and what it cannot measure.

October 9, 2026 · 7 min read · 15 sources Read article → Evidence

Thymosin alpha-1 after TESTS: two large negative trials

It is sold as an "immune optimizer". It is approved in more than 35 countries for hepatitis B and C. But two large double-blind trials, in sepsis and in pancreatitis, showed no benefit. And in patients under 60 a signal pointed the other way.

October 9, 2026 · 3 min read · 15 sources Read article → Evidence

5-amino-1MQ: what the NNMT inhibitor does and where the evidence ends

5-amino-1MQ sits in peptide catalogs, but it is a small molecule that blocks the enzyme NNMT. In mice it was associated with less fat, better metabolism and stronger aged muscle; in humans there are still no published trials.

October 9, 2026 · 4 min read · 13 sources Read article →
Evidence

SNAP-8 and argireline: "topical Botox" under the microscope

SNAP-8 and its predecessor, argireline, mimic a fragment of SNAP-25 to dampen the contraction behind expression lines. The mechanism is elegant and the human trials are positive, but small; the skin is the main barrier.

October 9, 2026 · 5 min read · 14 sources Read article → Clinical practice

Peptide stability: from lyophilized powder to reconstituted vial

A well-kept peptide is a reliable data point. The chemistry of degradation is well understood: moisture, temperature, light, pH, surfaces and agitation. This is the protocol that follows from the literature and from the labels of approved peptides.

October 9, 2026 · 5 min read · 16 sources Read article → Clinical practice

GLP-1s: interactions, bone, micronutrients and the "microdosing" fad

What gets missed in the clinic: hypoglycemia with sulfonylureas, rising levothyroxine, a shifting INR, falling vitamin D, bone density, and a trend with no trial behind it.

October 9, 2026 · 3 min read · 16 sources Read article → Clinical practice

Full stomach despite fasting: GLP-1s, sedation and the 2024 reversal

In 2023 the ASA asked for weekly GLP-1s to be held for a week before surgery. In 2024 five societies said the opposite. Gastric ultrasound data from 2026 show why the debate is not over.

October 9, 2026 · 3 min read · 15 sources Read article →
Evidence

Epitalon: Khavinson's program, telomerase and what still needs replication

Epitalon (Ala-Glu-Asp-Gly) is the product of more than four decades of research by Vladimir Khavinson's group in St. Petersburg. Its hypothesis is coherent and its animal safety reports are favorable; what is missing is independent replication and controlled human trials.

October 9, 2026 · 5 min read · 14 sources Read article → Clinical practice

GLP-1s and thyroid cancer: from rat C-cells to Nordic registries

The boxed warning is still on the label. A French study found a signal; the large registries that followed did not. What we know in 2026, and what still cannot be ruled out.

October 9, 2026 · 3 min read · 16 sources Read article → Clinical practice

Compounded GLP-1s: salts, impurities and antibodies

990 adverse-event reports with compounded semaglutide and more than 730 with tirzepatide. A new impurity in B12 blends. And a little-known fact: even the branded product triggered antibodies in nearly two out of three patients in its trials.

October 9, 2026 · 3 min read · 15 sources Read article → Market

Glutathione for skin lightening: what the trials show

Glutathione is a tripeptide sold as capsules, creams and intravenous drips to lighten the skin. Oral and topical trials show modest effects; the intravenous route has a single controlled trial and several official warnings.

October 9, 2026 · 5 min read · 15 sources Read article →
Market

What is really in the vial? What the labs found

Semaglutide at 7.7% purity. Arsenic and lead. Bacteria. Growth hormone with less than the label says. What studies found when they tested peptides bought outside the regulated supply chain.

October 9, 2026 · 3 min read · 16 sources Read article → Evidence

Intranasal oxytocin: anatomy of a replication crisis

The "love hormone" promised to improve social behavior, autism and even obesity. When the large trials came, the main effects were not confirmed. A case study in how to read the evidence for a peptide.

October 9, 2026 · 3 min read · 14 sources Read article →
Trends

RAADfest: two women in critical care after peptide injections

At a longevity festival in Las Vegas, two attendees received peptide blends at a booth. One reached the hospital already intubated. Fines came seven months later, but the vials were never tested.

October 9, 2026 · 2 min read · 15 sources Read article →